Goldman Sachs Group Inc Relmada Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

$605 Billion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$3.1 - $6.8 $366,553 - $804,052	118,243 New	118,243 $549,000
Q3 2023 May 14, 2024	BUY	$2.48 - $3.79 $32,235 - $49,262	12,998 New	12,998 $38,000
Q3 2023 Nov 14, 2023	SELL	$2.48 - $3.79 $370,385 - $566,032	-149,349 Reduced 91.99%	12,998 $38,000
Q2 2023 May 14, 2024	SELL	$2.22 - $3.54 $83,198 - $132,668	-37,477 Reduced 18.76%	162,347 $399,000
Q2 2023 Aug 14, 2023	SELL	$2.22 - $3.54 $83,198 - $132,668	-37,477 Reduced 18.76%	162,347 $399,000
Q1 2023 May 14, 2024	SELL	$2.24 - $4.76 $138,622 - $294,572	-61,885 Reduced 23.65%	199,824 $451,000
Q1 2023 May 11, 2023	SELL	$2.24 - $4.76 $138,622 - $294,572	-61,885 Reduced 23.65%	199,824 $451,000
Q4 2022 May 14, 2024	BUY	$2.17 - $35.84 $413,085 - $6.82 Million	190,362 Added 266.81%	261,709 $913,000
Q4 2022 Feb 13, 2023	BUY	$2.17 - $35.84 $413,085 - $6.82 Million	190,362 Added 266.81%	261,709 $913,000
Q3 2022 May 14, 2024	SELL	$18.3 - $37.02 $2.06 Million - $4.18 Million	-112,827 Reduced 61.26%	71,347 $2.64 Million
Q3 2022 Nov 10, 2022	SELL	$18.3 - $37.02 $2.06 Million - $4.18 Million	-112,827 Reduced 61.26%	71,347 $2.64 Million
Q2 2022 May 14, 2024	BUY	$16.5 - $30.34 $3.04 Million - $5.59 Million	184,174 New	184,174 $3.5 Million
Q2 2022 Aug 15, 2022	BUY	$16.5 - $30.34 $2.56 Million - $4.7 Million	154,883 Added 528.77%	184,174 $3.5 Million
Q1 2022 May 16, 2022	SELL	$16.72 - $26.99 $919,549 - $1.48 Million	-54,997 Reduced 65.25%	29,291 $791,000
Q4 2021 Feb 14, 2022	SELL	$16.93 - $26.82 $30,372 - $48,115	-1,794 Reduced 2.08%	84,288 $1.9 Million
Q3 2021 Nov 10, 2021	BUY	$21.86 - $34.77 $1.88 Million - $2.99 Million	86,082 New	86,082 $2.26 Million

Others Institutions Holding RLMD

# of Institutions

Shares Held

12.3M

Call Options Held

229K

Put Options Held

138K

View Full List

About RELMADA THERAPEUTICS, INC.

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $10.9M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

More about RLMD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account